Switching from Tikosyn (Dofetilide) to Amiodarone: Washout Period
You should wait at least 2 days after discontinuing dofetilide before starting amiodarone. This washout period allows for adequate clearance of dofetilide to minimize the risk of additive QT prolongation and proarrhythmic effects when transitioning between these Class III antiarrhythmic agents.
Rationale for the 2-Day Washout
The FDA-approved prescribing information for Tikosyn (dofetilide) explicitly states: "If TIKOSYN needs to be discontinued to allow dosing of other potentially interacting drug(s), a washout period of at least two days should be followed before starting the other drug(s)" 111. This recommendation is based on dofetilide's pharmacokinetic profile and the need to minimize overlapping QT-prolonging effects.
Key Pharmacokinetic Considerations:
- Dofetilide elimination half-life: Approximately 10 hours in patients with normal renal function
- Time to steady-state clearance: After 2 days (approximately 5 half-lives), over 95% of dofetilide will be eliminated from the body
- Renal excretion: Dofetilide is primarily eliminated by the kidneys, so patients with impaired renal function may require longer washout periods
Clinical Implementation Algorithm
Step 1: Discontinue Dofetilide
- Stop all dofetilide doses immediately
- Document the last dose timing and QTc interval
Step 2: Monitor During Washout Period
- Minimum 2-day waiting period before initiating amiodarone
- Monitor ECG and QTc interval during this period
- Ensure QTc returns toward baseline (ideally <500 msec)
- Consider rate control agents if needed for symptomatic atrial fibrillation during the washout
Step 3: Assess Renal Function
- If creatinine clearance is <60 mL/min, consider extending the washout period to 3-4 days due to prolonged dofetilide elimination
- Verify electrolytes (potassium and magnesium) are within normal range before starting amiodarone
Step 4: Initiate Amiodarone
After the 2-day washout (or longer if renal impairment exists):
- Loading regimen: 600-800 mg daily in divided doses until 10 g total load achieved 222
- Alternative loading: 400-600 mg daily over 2-4 weeks 34
- Maintenance: 200-400 mg daily 33
Important Safety Considerations
Why This Direction is Safer Than the Reverse
The transition from dofetilide to amiodarone is considerably safer and simpler than the reverse direction. When switching FROM amiodarone TO dofetilide, FDA guidelines mandate waiting at least 3 months OR until amiodarone plasma levels fall below 0.3 mcg/mL 111. This is due to amiodarone's:
- Extremely long elimination half-life (26-107 days for oral dosing) 56
- Extensive tissue accumulation
- Unpredictable pharmacokinetics
Recent research suggests this 3-month washout may be shortened in select patients with implantable cardioverter-defibrillators under close monitoring 78, but the standard remains 3 months.
Monitoring Requirements During Transition
During the 2-day washout:
- Daily ECG with QTc measurement
- Serum potassium and magnesium levels (correct if low)
- Symptom assessment for arrhythmia recurrence
After starting amiodarone:
- Baseline ECG, liver function tests, thyroid function tests, chest X-ray 9
- Monitor for bradycardia and QT prolongation in first 24-48 hours
- Follow-up thyroid and liver function every 6 months 9
- Annual chest radiograph for pulmonary toxicity surveillance 22
Common Pitfalls to Avoid
- Do not overlap the medications: Both drugs prolong the QT interval through potassium channel blockade, creating additive risk for torsades de pointes
- Do not rush the transition in renal impairment: Patients with reduced creatinine clearance need longer washout periods
- Do not forget electrolyte optimization: Hypokalemia and hypomagnesemia significantly increase proarrhythmic risk with both agents
- Do not initiate amiodarone outpatient without baseline testing: Obtain baseline thyroid, liver, and pulmonary function before starting
Special Clinical Scenarios
Urgent Need for Rhythm Control
If immediate rhythm control is needed during the 2-day washout:
- Use rate-control agents (beta-blockers, calcium channel blockers, digoxin) 33
- Consider electrical cardioversion if hemodynamically unstable
- Do NOT start amiodarone early to avoid overlapping QT effects
Patients with Structural Heart Disease
Amiodarone is particularly appropriate for patients with:
These patients should still observe the 2-day washout but may benefit most from the transition given amiodarone's superior safety profile in structural heart disease compared to dofetilide.